CytoSorbents’ $11.5 Million Shelf Takedown

Cooley advised the underwriters on CytoSorbents’ $11.5 million shelf takedown of 2,555,555 shares of common stock.

Cowen and Company acted as the sole book-running manager for the offering. Aegis Capital Corp, Wainwright & Co., B. Riley & Co., Maxim Group LLC and Northland Capital Markets acted as co-managers.

CytoSorbents, which trades on The NASDAQ Capital Market under the symbol “CTSO,” is a leader in critical care immunotherapy. The company’s blood purification technology is approved in the European Union, with distribution in 29 countries around the world. CytoSorb is an extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.

Cooley has advised with a team including Div Gupta (Picture), Daniel I. Goldberg, Josh Kaufman, Pia Kaur, Esther Cho, Sarah diFrancesca, Bill Christiansen, Aaron Nudelman, Mark Windfeld-Hansen, Stephanie Gentile and Francis Wheeler.

Involved fees earner: Div Gupta – Cooley LLP; Daniel Goldberger – Cooley LLP; Josh Kaufman – Cooley LLP; Pia Kaur – Cooley LLP; Esther Cho – Cooley LLP; Francis Wheeler – Cooley LLP; Sarah diFrancesca – Cooley LLP; Bill Christiansen – Cooley LLP; Aaron Nudelman – Cooley LLP; Mark Windfeld-Hansen – Cooley LLP; Stephanie Gentile – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Cowen and Company; B. Riley & Co; H.C. Wainwright & Co.; Aegis Capital Corporation; Maxim Group LLC;


Author: Ambrogio Visconti